CILP1 as a biomarker for right ventricular dysfunction in patients with ischemic cardiomyopathy

Keranov, Stanislav; Jafari, Leili; Haen, Saskia; Vietheer, Julia; Kriechbaum, Steffen; Dörr, Oliver; Liebetrau, Christoph; Troidl, Christian; Rutsatz, Wiebke; Rieth, Andreas; Hamm, Christian W.; Nef, Holger; Rolf, Andreas; Keller, Till

doi:10.1002/pul2.12062

Cited by 6 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Until now, only three manuscripts have reported circulating CILP-1 levels in healthy individuals [1,8,13]. They used the commercially available kits from MyBiosource and Cusabio [1,8].…”

Section: Comparison Of Cilp-1 Levels In CV Disease and Hfmentioning

confidence: 99%

“…NT-proBNP, predominantly released by the LV upon myocardial stretch, is a biomarker with an excellent prognostic ability in HF [7]. However, NT-proBNP cannot entirely grasp HFrEF-related RVD [8]. A biomarker specifically indicating RV stress could further refine risk assessment in advanced HFrEF.…”

Section: Introductionmentioning

confidence: 99%

“…To date, circulating CILP-1 has only been investigated in a small number of human studies with cardiac pathologies. CILP-1 is elevated in ischemic cardiomyopathy or PH [1,8]. In ischemic cardiomyopathy, increased CILP-1 was associated with adverse RV remodeling, while no association with LV parameters was observed.…”

Section: Introductionmentioning

confidence: 99%

“…In ischemic cardiomyopathy, increased CILP-1 was associated with adverse RV remodeling, while no association with LV parameters was observed. CILP-1 was also a good predictor of a right ventricular function (RVF) of <40%, suggesting that CILP-1 might be a new non-invasive biomarker for RVD [8]. A subsequent study examining chronic HF patients with a left ventricular ejection fraction (LVEF) of ≤50% reported that CILP-1 was a risk factor for increased mortality over a 1-year period [14].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

CILP-1 Is a Biomarker for Backward Failure and Right Ventricular Dysfunction in HFrEF

Weidenhammer,

Prausmüller,

Partsch

et al. 2023

Cells

View full text Add to dashboard Cite

Background: CILP-1 regulates myocardial fibrotic response and remodeling and was reported to indicate right ventricular dysfunction (RVD) in pulmonary hypertension (PH) and heart failure (HF). This study examines CILP-1 as a potential biomarker for RVD and prognosis in heart failure with reduced ejection fraction (HFrEF) patients on guideline-directed medical therapy. Methods: CILP-1 levels were measured in 610 HFrEF patients from a prospective registry with biobanking (2016–2022). Correlations with echocardiographic and hemodynamic data and its association with RVD and prognosis were analyzed. Results: The median age was 62 years (Q1–Q3: 52–72), 77.7% of patients were male, and the median NT-proBNP was 1810 pg/mL (Q1–Q3: 712–3962). CILP-1 levels increased with HF severity, as indicated by NT-proBNP and NYHA class (p < 0.0001, for both). CILP-1 showed a weak–moderate direct association with increased left ventricular filling pressures and its sequalae, i.e., backward failure (LA diameter rs = 0.15, p = 0.001; sPAP rs = 0.28, p = 0.010; RVF rs = 0.218, p < 0.0001), but not with cardiac index (CI) and systemic vascular resistance (SVR). CILP-1 trended as a risk factor for all-cause mortality (crude HR for 500 pg/mL increase: 1.03 (95%CI: 1.00–1.06), p = 0.053) but lost significance when it was adjusted for NT-proBNP (adj. HR: 1.00 (95%CI: 1.00–1.00), p = 0.770). No association with cardiovascular hospitalization was observed. Conclusions: CILP-1 correlates with HFrEF severity and may indicate an elevated risk for all-cause mortality, though it is not independent from NT-proBNP. Increased CILP-1 is associated with backward failure and RVD rather than forward failure. Whether CILP-1 release in this context is based on elevated pulmonary pressures or is specific to RVD needs to be further investigated.

show abstract

“…Until now, only three manuscripts have reported circulating CILP-1 levels in healthy individuals [1,8,13]. They used the commercially available kits from MyBiosource and Cusabio [1,8].…”

Section: Comparison Of Cilp-1 Levels In CV Disease and Hfmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

CILP-1 Is a Biomarker for Backward Failure and Right Ventricular Dysfunction in HFrEF

Weidenhammer,

Prausmüller,

Partsch

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

“…Patients who present with a RV infarct will have an increase in troponin levels ( 36 ). Additionally, cartilage intermediate layer protein 1, a novel biomarker has been associated with RV dysfunction in patients with pulmonary hypertension and ischemic cardiomyopathy ( 37 , 38 ).…”

Section: Current Assessment Modalitiesmentioning

confidence: 99%

Assessment and diagnosis of right ventricular failure—retrospection and future directions

Sato

Ijuin

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The right ventricle (RV) has a critical role in hemodynamics and right ventricular failure (RVF) often leads to poor clinical outcome. Despite the clinical importance of RVF, its definition and recognition currently rely on patients’ symptoms and signs, rather than on objective parameters from quantifying RV dimensions and function. A key challenge is the geometrical complexity of the RV, which often makes it difficult to assess RV function accurately. There are several assessment modalities currently utilized in the clinical settings. Each diagnostic investigation has both advantages and limitations according to its characteristics. The purpose of this review is to reflect on the current diagnostic tools, consider the potential technological advancements and propose how to improve the assessment of right ventricular failure. Advanced technique such as automatic evaluation with artificial intelligence and 3-dimensional assessment for the complex RV structure has a potential to improve RV assessment by increasing accuracy and reproducibility of the measurements. Further, noninvasive assessments for RV-pulmonary artery coupling and right and left ventricular interaction are also warranted to overcome the load-related limitations for the accurate evaluation of RV contractile function. Future studies to cross-validate the advanced technologies in various populations are required.

show abstract

CILP1 as a biomarker for right ventricular dysfunction in patients with ischemic cardiomyopathy

et al. 2022

Self Cite

View full text Add to dashboard Cite

The aim of this study was to evaluate the cartilage intermediate layer protein 1 (CILP1) as a biomarker of right ventricular dysfunction in patients with ischemic cardiomyopathy (ICM). CILP1 plasma concentrations were measured in 98 patients with ICM and 30 controls without any cardiac abnormalities. All participants underwent cardiac magnetic resonance imaging. Median CILP1 concentrations were higher in ICM than in controls. In the tertile analysis, low right ventricular ejection fraction (RVEF) and high right ventricular end‐systolic volume index and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) were associated with higher CILP1 levels in ICM. However, there were no associations between CILP1 concentrations and left ventricular (LV) parameters in this group. In receiver‐operating characteristic (ROC) analysis CILP1 was a good predictor of RVEF < 40% with an optimal cut‐off value of 3545 pg/ml in ICM, whereas it was not predictive of LV ejection fraction (LVEF) < 40% (area under the curve [AUC] = 0.57) There was no significant difference between the ROC curves of CILP1 (AUC = 0.72) and NT‐proBNP (AUC = 0.77) for RVEF < 40% (p = 0.42). In multivariable regression analysis, RVEF was the only independent predictor of elevated CILP1. CILP1 and LVEF were the only independent predictors of RVEF < 40% in ICM. Our analysis demonstrates the potential role of CILP1 as a novel cardiac biomarker of prognostically relevant RV dysfunction in patients with ICM.

show abstract

CILP1 as a biomarker for right ventricular dysfunction in patients with ischemic cardiomyopathy

Cited by 6 publications

References 39 publications

CILP-1 Is a Biomarker for Backward Failure and Right Ventricular Dysfunction in HFrEF

CILP-1 Is a Biomarker for Backward Failure and Right Ventricular Dysfunction in HFrEF

Assessment and diagnosis of right ventricular failure—retrospection and future directions

CILP1 as a biomarker for right ventricular dysfunction in patients with ischemic cardiomyopathy

Contact Info

Product

Resources

About